Drug-releasing contact lens for allergy itch relief receives approval in Japan
Click Here to Manage Email Alerts
The Japanese Ministry of Health, Labour and Welfare approved Johnson & Johnson Vision’s Acuvue Theravision with Ketotifen, a drug-releasing combination contact lens designed for both vision correction and allergic eye itch relief.
This is the first regulatory approval for a drug-releasing technology with an antihistamine for patients with allergic conjunctivitis, according to a press release from Johnson & Johnson Vision.
The daily disposable contact lens is made of etafilcon A material, the company said in the release.
“This approval marks another significant milestone in Johnson & Johnson Vision’s legacy of rethinking what’s possible with contact lenses and bringing forward innovations to help eye care practitioners better meet the needs of their patients around the world,” Xiao-Yu Song, MD, PhD, global head of research and development at Johnson & Johnson Vision, said in the release. “Our goal at Johnson & Johnson Vision is to change the trajectory of eye health, and we will continue to drive new innovation and technologies that correct, enhance and restore people’s vision over their lifetimes.”
Johnson & Johnson Vision stated in the release that the company is continuing to work with health authorities worldwide to attain approval for Acuvue Theravision with Ketotifen.
“Over 40% of people suffer from eye allergies, and of those, 80% feel frustrated when allergies interfere with contact lens wear,” Brian Pall, OD, MS, FAAO, director of clinical science at Johnson & Johnson Vision Care, said in the release. “We’re proud to bring forward a new contact lens that simultaneously provides vision correction and relief of allergic eye itch, without the need for allergy eye drops.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts